No Direct Comparison Study Exists Between Alprazolam (Xanax) and Quetiapine (Seroquel) for GAD
After systematic review of the available evidence, there is no published head-to-head randomized controlled trial directly comparing alprazolam (Xanax) versus quetiapine (Seroquel) for the treatment of generalized anxiety disorder.
What the Evidence Shows
Individual Drug Efficacy Data Only
The available literature contains:
Alprazolam (Xanax): Demonstrated efficacy versus placebo in GAD through multiple double-blind studies using doses up to 4 mg/day, with significant improvements on Hamilton Anxiety Rating Scale and other psychometric measures 1. A 1993 review found alprazolam comparable to other active agents for anxiety disorders 2.
Quetiapine (Seroquel): Extended-release formulations at 50-150 mg/day showed efficacy versus placebo in GAD, with significant HAM-A score improvements at week 8 3. Meta-analyses confirm quetiapine-XR efficacy for GAD 4, 5.
Network Meta-Analysis Findings
The most recent 2025 network meta-analysis of anxiolytics for GAD included multiple benzodiazepines but did not include quetiapine in the comparison network 6. This analysis found all benzodiazepines generally efficacious versus placebo, with clomipramine showing highest efficacy but poorest acceptability.
A separate 2025 benzodiazepine-specific network meta-analysis found no significant differences between individual benzodiazepines for GAD efficacy, though all were superior to placebo 7.
Clinical Context
Why This Comparison Doesn't Exist
These medications occupy fundamentally different positions in GAD treatment algorithms:
- Alprazolam is a benzodiazepine used for acute anxiety management or short-term adjunctive therapy
- Quetiapine is a second-generation antipsychotic studied as monotherapy or augmentation for treatment-resistant GAD
Current guidelines recommend SSRIs/SNRIs as first-line GAD treatment in adults 8. Neither alprazolam nor quetiapine represents standard first-line monotherapy, making a direct comparison study unlikely to be prioritized by researchers.
Practical Implications
The absence of comparative data reflects different clinical niches: benzodiazepines like alprazolam provide rapid symptom relief but carry dependence risks with chronic use, while quetiapine is investigated primarily for refractory cases where standard antidepressants have failed 5, 9.